drugset / Trial / NCT00820950
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
Timeline
- Start
- 2007-05-31
- Primary completion
- 2009-01-31
- Completion
- 2009-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcipotriol | Small molecule | 0.005 % | Topical |
| Subject | Ruxolitinib | Small molecule | 0.5 % | Topical |
| Subject | Ruxolitinib | Small molecule | 1 % | Topical |
| Subject | Ruxolitinib | Small molecule | 1.5 % | Topical |
| Subject | betamethasone dipropionate | Small molecule | 0.05 % | Topical |